https://stock.noler.com/us/stock/pharmerica-corp https://stock.noler.com/us/stock/pharmerica-corp/accounts-and-notes-receivable-net https://stock.noler.com/us/stock/pharmerica-corp/accounts-payable https://stock.noler.com/us/stock/pharmerica-corp/accounts-payable-trade-current https://stock.noler.com/us/stock/pharmerica-corp/accounts-receivable https://stock.noler.com/us/stock/pharmerica-corp/accrual-at-carrying-value https://stock.noler.com/us/stock/pharmerica-corp/accrual-provision https://stock.noler.com/us/stock/pharmerica-corp/accrued-income-taxes-current https://stock.noler.com/us/stock/pharmerica-corp/accumulated-depreciation https://stock.noler.com/us/stock/pharmerica-corp/acquired-cash-and-equivalents https://stock.noler.com/us/stock/pharmerica-corp/acquired-financial-liabilities https://stock.noler.com/us/stock/pharmerica-corp/acquisition-acquisition-related-costs https://stock.noler.com/us/stock/pharmerica-corp/acquisition-bargain-purchase-gain-recognized-amount https://stock.noler.com/us/stock/pharmerica-corp/acquisition-consideration-transferred https://stock.noler.com/us/stock/pharmerica-corp/acquisition-integration-related-costs https://stock.noler.com/us/stock/pharmerica-corp/acquisition-provisional-information-initial-accounting-incomplete-adjustment-intangibles https://stock.noler.com/us/stock/pharmerica-corp/acquisition-separately-recognized-transactions-additional-disclosures-acquisition-cost-expensed https://stock.noler.com/us/stock/pharmerica-corp/acquisitions https://stock.noler.com/us/stock/pharmerica-corp/additional-paid-in-capital https://stock.noler.com/us/stock/pharmerica-corp/adjustment-for-amortization https://stock.noler.com/us/stock/pharmerica-corp/adjustments-related-to-tax-withholding-for-share-based-compensation https://stock.noler.com/us/stock/pharmerica-corp/allowance-for-doubtful-accounts-receivable-current https://stock.noler.com/us/stock/pharmerica-corp/amortization https://stock.noler.com/us/stock/pharmerica-corp/amortization-of-financing-costs https://stock.noler.com/us/stock/pharmerica-corp/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/pharmerica-corp/asset-impairment-charges https://stock.noler.com/us/stock/pharmerica-corp/basic-shares https://stock.noler.com/us/stock/pharmerica-corp/billed-contract-receivables https://stock.noler.com/us/stock/pharmerica-corp/business-acquisition-pro-forma-earnings-per-share-basic https://stock.noler.com/us/stock/pharmerica-corp/business-acquisition-pro-forma-earnings-per-share-diluted https://stock.noler.com/us/stock/pharmerica-corp/business-acquisition-purchase-price-allocation-goodwill-expected-tax-deductible-amount https://stock.noler.com/us/stock/pharmerica-corp/business-acquisitions-pro-forma-net-income-loss https://stock.noler.com/us/stock/pharmerica-corp/business-acquisitions-pro-forma-revenue https://stock.noler.com/us/stock/pharmerica-corp/buyback-authorization-remaining https://stock.noler.com/us/stock/pharmerica-corp/buybacks-payments-for-repurchase-of-equity https://stock.noler.com/us/stock/pharmerica-corp/buybacks-shares-repurchased https://stock.noler.com/us/stock/pharmerica-corp/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/pharmerica-corp/buybacks-treasury-stock-cost https://stock.noler.com/us/stock/pharmerica-corp/capital-lease-obligations-incurred https://stock.noler.com/us/stock/pharmerica-corp/capital-leased-assets-gross https://stock.noler.com/us/stock/pharmerica-corp/capital-leases-future-minimum-payments-due https://stock.noler.com/us/stock/pharmerica-corp/capital-leases-future-minimum-payments-due-current https://stock.noler.com/us/stock/pharmerica-corp/capital-leases-future-minimum-payments-due-in-five-years https://stock.noler.com/us/stock/pharmerica-corp/capital-leases-future-minimum-payments-due-in-four-years https://stock.noler.com/us/stock/pharmerica-corp/capital-leases-future-minimum-payments-due-in-three-years https://stock.noler.com/us/stock/pharmerica-corp/capital-leases-future-minimum-payments-due-in-two-years https://stock.noler.com/us/stock/pharmerica-corp/capital-leases-future-minimum-payments-due-thereafter https://stock.noler.com/us/stock/pharmerica-corp/capital-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/pharmerica-corp/capitalized-computer-software-additions https://stock.noler.com/us/stock/pharmerica-corp/capitalized-computer-software-net https://stock.noler.com/us/stock/pharmerica-corp/cash-and-equivalents https://stock.noler.com/us/stock/pharmerica-corp/cash-flow-breakdown https://stock.noler.com/us/stock/pharmerica-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmerica-corp/common-stock-value https://stock.noler.com/us/stock/pharmerica-corp/comprehensive-income https://stock.noler.com/us/stock/pharmerica-corp/concentration-risk-percentage https://stock.noler.com/us/stock/pharmerica-corp/construction-in-progress-gross https://stock.noler.com/us/stock/pharmerica-corp/contractual-obligation https://stock.noler.com/us/stock/pharmerica-corp/contractual-obligation-due-in-fifth-year https://stock.noler.com/us/stock/pharmerica-corp/contractual-obligation-due-in-fourth-year https://stock.noler.com/us/stock/pharmerica-corp/contractual-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/pharmerica-corp/contractual-obligation-due-in-second-year https://stock.noler.com/us/stock/pharmerica-corp/contractual-obligation-due-in-third-year https://stock.noler.com/us/stock/pharmerica-corp/contractual-obligation-future-minimum-payments-due-remainder-of-fiscal-year https://stock.noler.com/us/stock/pharmerica-corp/cost-of-goods-sold https://stock.noler.com/us/stock/pharmerica-corp/cost-of-property-repairs-and-maintenance https://stock.noler.com/us/stock/pharmerica-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/pharmerica-corp/current-assets https://stock.noler.com/us/stock/pharmerica-corp/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/pharmerica-corp/current-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmerica-corp/current-liabilities https://stock.noler.com/us/stock/pharmerica-corp/current-portion-of-long-term-debt https://stock.noler.com/us/stock/pharmerica-corp/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/pharmerica-corp/debt-issued https://stock.noler.com/us/stock/pharmerica-corp/debt-maturing-after-year-five https://stock.noler.com/us/stock/pharmerica-corp/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/pharmerica-corp/debt-maturing-in-year-five https://stock.noler.com/us/stock/pharmerica-corp/debt-maturing-in-year-four https://stock.noler.com/us/stock/pharmerica-corp/debt-maturing-in-year-three https://stock.noler.com/us/stock/pharmerica-corp/debt-maturing-in-year-two https://stock.noler.com/us/stock/pharmerica-corp/debt-maturing-remainder-of-fiscal-year https://stock.noler.com/us/stock/pharmerica-corp/debt-repaid https://stock.noler.com/us/stock/pharmerica-corp/deferred-compensation-arrangement-with-individual-compensation-expense https://stock.noler.com/us/stock/pharmerica-corp/deferred-compensation-liability-classified-noncurrent https://stock.noler.com/us/stock/pharmerica-corp/deferred-compensation-share-based-arrangements-liability-classified-noncurrent https://stock.noler.com/us/stock/pharmerica-corp/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmerica-corp/deferred-finance-costs-gross https://stock.noler.com/us/stock/pharmerica-corp/deferred-finance-costs-net https://stock.noler.com/us/stock/pharmerica-corp/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmerica-corp/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-assets-liabilities-net-noncurrent https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-assets-net https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-assets-net-current https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-assets-net-noncurrent https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-assets-operating-loss-carryforwards-state-and-local https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-liabilities https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-liabilities-goodwill-and-intangible-assets-goodwill https://stock.noler.com/us/stock/pharmerica-corp/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/pharmerica-corp/defined-benefit-plan-contributions-by-employer https://stock.noler.com/us/stock/pharmerica-corp/depreciation https://stock.noler.com/us/stock/pharmerica-corp/depreciation-and-amortization https://stock.noler.com/us/stock/pharmerica-corp/diluted-shares https://stock.noler.com/us/stock/pharmerica-corp/effective-tax-rate https://stock.noler.com/us/stock/pharmerica-corp/employee-related-liabilities-current https://stock.noler.com/us/stock/pharmerica-corp/entity-wide-revenue-major-customer-percentage https://stock.noler.com/us/stock/pharmerica-corp/eps https://stock.noler.com/us/stock/pharmerica-corp/eps-basic https://stock.noler.com/us/stock/pharmerica-corp/estimate-of-possible-loss https://stock.noler.com/us/stock/pharmerica-corp/excess-tax-benefit-from-share-based-compensation-financing-activities https://stock.noler.com/us/stock/pharmerica-corp/excess-tax-benefit-from-share-based-compensation-operating-activities https://stock.noler.com/us/stock/pharmerica-corp/extinguishment-of-debt-gain-loss-net-of-tax https://stock.noler.com/us/stock/pharmerica-corp/fair-value-of-assets-acquired https://stock.noler.com/us/stock/pharmerica-corp/financing-cash-flow https://stock.noler.com/us/stock/pharmerica-corp/financing-receivable-percent-past-due https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-acquired https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-change https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-fair-value-disclosure https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/pharmerica-corp/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/pharmerica-corp/finitelived-intangible-assets-acquired https://stock.noler.com/us/stock/pharmerica-corp/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/pharmerica-corp/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/pharmerica-corp/goodwill https://stock.noler.com/us/stock/pharmerica-corp/goodwill-acquired https://stock.noler.com/us/stock/pharmerica-corp/goodwill-and-intangible-asset-impairment https://stock.noler.com/us/stock/pharmerica-corp/goodwill-purchase-accounting-adjustments https://stock.noler.com/us/stock/pharmerica-corp/gross-profit https://stock.noler.com/us/stock/pharmerica-corp/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/pharmerica-corp/income-tax https://stock.noler.com/us/stock/pharmerica-corp/income-taxes-paid https://stock.noler.com/us/stock/pharmerica-corp/income-taxes-receivable https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-accounts-and-other-receivables https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-accrued-income-taxes-payable https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-employee-related-liabilities https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-income-taxes-receivable https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-inventories https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-other-accrued-liabilities https://stock.noler.com/us/stock/pharmerica-corp/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/pharmerica-corp/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/pharmerica-corp/information-technology-and-data-processing https://stock.noler.com/us/stock/pharmerica-corp/insider-transactions-other https://stock.noler.com/us/stock/pharmerica-corp/insider-transactions-stock-units https://stock.noler.com/us/stock/pharmerica-corp/insurance-recoveries https://stock.noler.com/us/stock/pharmerica-corp/insurance-settlements-receivable-current https://stock.noler.com/us/stock/pharmerica-corp/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/pharmerica-corp/interest-expense https://stock.noler.com/us/stock/pharmerica-corp/interest-paid-net https://stock.noler.com/us/stock/pharmerica-corp/inventory https://stock.noler.com/us/stock/pharmerica-corp/investing-cash-flow https://stock.noler.com/us/stock/pharmerica-corp/leasehold-improvements-gross https://stock.noler.com/us/stock/pharmerica-corp/letters-of-credit-outstanding-amount https://stock.noler.com/us/stock/pharmerica-corp/litigation-reserve https://stock.noler.com/us/stock/pharmerica-corp/litigation-settlement-amount https://stock.noler.com/us/stock/pharmerica-corp/litigation-settlement-expense https://stock.noler.com/us/stock/pharmerica-corp/long-term-debt https://stock.noler.com/us/stock/pharmerica-corp/loss-from-catastrophes https://stock.noler.com/us/stock/pharmerica-corp/net-cash-from-financing-activities https://stock.noler.com/us/stock/pharmerica-corp/net-cash-from-investing-activities https://stock.noler.com/us/stock/pharmerica-corp/net-cash-from-operating-activities https://stock.noler.com/us/stock/pharmerica-corp/net-change-in-cash https://stock.noler.com/us/stock/pharmerica-corp/net-income https://stock.noler.com/us/stock/pharmerica-corp/notes-receivable-net https://stock.noler.com/us/stock/pharmerica-corp/number-of-operating-segments https://stock.noler.com/us/stock/pharmerica-corp/number-of-reportable-segments https://stock.noler.com/us/stock/pharmerica-corp/number-of-states-in-which-entity-operates https://stock.noler.com/us/stock/pharmerica-corp/oci-derivatives-qualifying-as-hedges-net-of-tax-change https://stock.noler.com/us/stock/pharmerica-corp/operating-cash-flow https://stock.noler.com/us/stock/pharmerica-corp/operating-income https://stock.noler.com/us/stock/pharmerica-corp/operating-lease-payments-due https://stock.noler.com/us/stock/pharmerica-corp/operating-lease-payments-due-current https://stock.noler.com/us/stock/pharmerica-corp/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/pharmerica-corp/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/pharmerica-corp/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/pharmerica-corp/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/pharmerica-corp/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/pharmerica-corp/operating-leases-rent-expense-net https://stock.noler.com/us/stock/pharmerica-corp/other-accrued-liabilities-current https://stock.noler.com/us/stock/pharmerica-corp/other-employee-related-liabilities-current-and-noncurrent https://stock.noler.com/us/stock/pharmerica-corp/other-noncash-expense https://stock.noler.com/us/stock/pharmerica-corp/other-noncash-income-expense https://stock.noler.com/us/stock/pharmerica-corp/other-noncurrent-assets https://stock.noler.com/us/stock/pharmerica-corp/other-noncurrent-liabilities https://stock.noler.com/us/stock/pharmerica-corp/other-nonrecurring-expense https://stock.noler.com/us/stock/pharmerica-corp/other-receivables https://stock.noler.com/us/stock/pharmerica-corp/paid-in-capital-share-based-compensation-restricted-stock-units-requisite-service-period-recognition https://stock.noler.com/us/stock/pharmerica-corp/paid-in-capital-share-based-compensation-stock-options-requisite-service-period-recognition https://stock.noler.com/us/stock/pharmerica-corp/paid-in-capital-tax-effect-from-share-based-compensation https://stock.noler.com/us/stock/pharmerica-corp/payments-for-proceeds-from-other-investing-activities https://stock.noler.com/us/stock/pharmerica-corp/payments-for-restructuring https://stock.noler.com/us/stock/pharmerica-corp/payments-of-debt-issuance-costs https://stock.noler.com/us/stock/pharmerica-corp/payments-to-acquire-other-property-plant-and-equipment https://stock.noler.com/us/stock/pharmerica-corp/payments-to-acquire-productive-assets https://stock.noler.com/us/stock/pharmerica-corp/pending-claims-number https://stock.noler.com/us/stock/pharmerica-corp/preferred-shares-facts https://stock.noler.com/us/stock/pharmerica-corp/preferred-stock-liquidation-preference https://stock.noler.com/us/stock/pharmerica-corp/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmerica-corp/preferred-stock-shares-authorized https://stock.noler.com/us/stock/pharmerica-corp/preferred-stock-shares-issued https://stock.noler.com/us/stock/pharmerica-corp/preferred-stock-value https://stock.noler.com/us/stock/pharmerica-corp/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/pharmerica-corp/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/pharmerica-corp/proceeds-from-divestiture-of-businesses https://stock.noler.com/us/stock/pharmerica-corp/proceeds-from-insurance-settlement-operating-activities https://stock.noler.com/us/stock/pharmerica-corp/proceeds-from-long-term-lines-of-credit https://stock.noler.com/us/stock/pharmerica-corp/proceeds-from-payments-for-other-financing-activities https://stock.noler.com/us/stock/pharmerica-corp/proceeds-from-repayments-of-lines-of-credit https://stock.noler.com/us/stock/pharmerica-corp/proceeds-from-sale-of-productive-assets https://stock.noler.com/us/stock/pharmerica-corp/proceeds-from-stock-issued https://stock.noler.com/us/stock/pharmerica-corp/property-plant-and-equipment-additions https://stock.noler.com/us/stock/pharmerica-corp/property-plant-and-equipment-disposals https://stock.noler.com/us/stock/pharmerica-corp/property-plant-and-equipment-fair-value-disclosure https://stock.noler.com/us/stock/pharmerica-corp/property-plant-and-equipment-gross https://stock.noler.com/us/stock/pharmerica-corp/property-plant-equipment https://stock.noler.com/us/stock/pharmerica-corp/public-float https://stock.noler.com/us/stock/pharmerica-corp/ratio-of-indebtedness-to-net-capital https://stock.noler.com/us/stock/pharmerica-corp/receivable-proceeds https://stock.noler.com/us/stock/pharmerica-corp/receivables-net-current https://stock.noler.com/us/stock/pharmerica-corp/repayments-of-long-term-capital-lease-obligations https://stock.noler.com/us/stock/pharmerica-corp/repayments-of-long-term-lines-of-credit https://stock.noler.com/us/stock/pharmerica-corp/restructuring-and-related-cost-incurred-cost https://stock.noler.com/us/stock/pharmerica-corp/restructuring-charges https://stock.noler.com/us/stock/pharmerica-corp/restructuring-costs-and-asset-impairment-charges https://stock.noler.com/us/stock/pharmerica-corp/restructuring-reserve https://stock.noler.com/us/stock/pharmerica-corp/restructuring-reserve-accrual-adjustment https://stock.noler.com/us/stock/pharmerica-corp/restructuring-reserve-accrual-adjustment-1 https://stock.noler.com/us/stock/pharmerica-corp/retained-earnings https://stock.noler.com/us/stock/pharmerica-corp/revenue https://stock.noler.com/us/stock/pharmerica-corp/self-insurance-reserve https://stock.noler.com/us/stock/pharmerica-corp/sga-expense https://stock.noler.com/us/stock/pharmerica-corp/share-price https://stock.noler.com/us/stock/pharmerica-corp/shareholders-equity https://stock.noler.com/us/stock/pharmerica-corp/shares-authorized https://stock.noler.com/us/stock/pharmerica-corp/shares-issued https://stock.noler.com/us/stock/pharmerica-corp/shares-issued-value-restricted-stock-award-forfeitures https://stock.noler.com/us/stock/pharmerica-corp/shares-subject-to-mandatory-redemption-settlement-terms-amount https://stock.noler.com/us/stock/pharmerica-corp/shipping-handling-and-transportation-costs https://stock.noler.com/us/stock/pharmerica-corp/stock-award-fair-value-assumptions-expected-volatility-rate-maximum https://stock.noler.com/us/stock/pharmerica-corp/stock-award-fair-value-assumptions-expected-volatility-rate-minimum https://stock.noler.com/us/stock/pharmerica-corp/stock-award-fair-value-assumptions-risk-free-interest-rate-maximum https://stock.noler.com/us/stock/pharmerica-corp/stock-award-fair-value-assumptions-risk-free-interest-rate-minimum https://stock.noler.com/us/stock/pharmerica-corp/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/pharmerica-corp/stock-award-options-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/pharmerica-corp/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/pharmerica-corp/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/pharmerica-corp/stock-award-rsu-aggregate-intrinsic-value-nonvested https://stock.noler.com/us/stock/pharmerica-corp/stock-award-rsu-aggregate-intrinsic-value-outstanding https://stock.noler.com/us/stock/pharmerica-corp/stock-award-rsu-forfeited-in-period https://stock.noler.com/us/stock/pharmerica-corp/stock-award-rsu-forfeitures-grant-date-fair-value https://stock.noler.com/us/stock/pharmerica-corp/stock-award-rsu-nonvested-grant-date-fair-value https://stock.noler.com/us/stock/pharmerica-corp/stock-award-rsu-nonvested-number https://stock.noler.com/us/stock/pharmerica-corp/stock-award-rsu-vested-in-period https://stock.noler.com/us/stock/pharmerica-corp/stock-award-rsu-vested-in-period-grant-date-fair-value https://stock.noler.com/us/stock/pharmerica-corp/stock-based-compensation https://stock.noler.com/us/stock/pharmerica-corp/stock-compensation-unrecognized-cost-share-based-awards-other-than-options https://stock.noler.com/us/stock/pharmerica-corp/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/pharmerica-corp/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/pharmerica-corp/stock-issued-shares-issued-value-restricted-stock-award-gross https://stock.noler.com/us/stock/pharmerica-corp/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/pharmerica-corp/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/pharmerica-corp/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/pharmerica-corp/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/pharmerica-corp/stock-options-exercisable-number https://stock.noler.com/us/stock/pharmerica-corp/stock-options-expirations-in-period https://stock.noler.com/us/stock/pharmerica-corp/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/pharmerica-corp/stock-options-grants-in-period https://stock.noler.com/us/stock/pharmerica-corp/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/pharmerica-corp/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/pharmerica-corp/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/pharmerica-corp/stock-options-outstanding-number https://stock.noler.com/us/stock/pharmerica-corp/stock-options-outstanding-remaining-term https://stock.noler.com/us/stock/pharmerica-corp/stock-repurchase-program-remaining-authorized-repurchase-amount https://stock.noler.com/us/stock/pharmerica-corp/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/pharmerica-corp/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/pharmerica-corp/tax-rate-reconciliation-deductions-qualified-production-activities https://stock.noler.com/us/stock/pharmerica-corp/tax-rate-reconciliation-nondeductible-expense-research-and-development https://stock.noler.com/us/stock/pharmerica-corp/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/pharmerica-corp/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/pharmerica-corp/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/pharmerica-corp/tax-rate-reconciliation-tax-settlements https://stock.noler.com/us/stock/pharmerica-corp/tax-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/pharmerica-corp/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/pharmerica-corp/tax-withholding-on-stock-awards https://stock.noler.com/us/stock/pharmerica-corp/total-assets https://stock.noler.com/us/stock/pharmerica-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/pharmerica-corp/total-long-term-debt https://stock.noler.com/us/stock/pharmerica-corp/treasury-stock-shares https://stock.noler.com/us/stock/pharmerica-corp/treasury-stock-value https://stock.noler.com/us/stock/pharmerica-corp/unrecognized-tax-benefits https://stock.noler.com/us/stock/pharmerica-corp/unsolicited-tender-offer-costs https://stock.noler.com/us/stock/pharmerica-corp/unusual-or-infrequent-item-earnings-per-share-impact-net https://stock.noler.com/us/stock/pharmerica-corp/utb-income-tax-penalties-and-interest-accrued https://stock.noler.com/us/stock/pharmerica-corp/valuation-allowances-and-reserves-change https://stock.noler.com/us/stock/pharmerica-corp/valuation-allowances-and-reserves-charged-to-cost-and-expense https://stock.noler.com/us/stock/pharmerica-corp/valuation-allowances-and-reserves-deductions https://stock.noler.com/us/stock/pharmerica-corp/valuation-allowances-and-reserves-recoveries https://stock.noler.com/us/stock/pharmerica-corp/write-off-of-deferred-debt-issuance-cost